课题基金 / 基金详情

Training Program for Applied Research and Development in Genomic Medicine

Training Program for Applied Research and Development in Genomic Medicine
基因组医学应用研究与开发培训计划
批准号:
10627222
负责人:
Julio David Duarte
金额:
$55.42万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-01-01 至 2028-04-30

项目摘要

项目成果

Julio David Duarte的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 医疗保健专业人员、基因组科学家和众多其他利益相关者正在拥抱 通过以下方式提供可能的、频率越来越高的医疗保健 利用基因组学来改善护理和患者结局。以确保我们能够继续扩大和 要充分发挥这种方法的潜力,需要一支高素质的临床医生队伍--科学家、科学家、 和临床医生共同努力,推动基因组医学的发现和实施。这 关于继续我校基因医学博士后培养计划的建议 基因组医学或范例的研究和开发,“利用我们的成功和教训” 从第一个供资周期中学到的经验:1)完善基因组医学的综合培训计划,其中 包括教学、研究、临床和职业发展活动;2)招聘有前途的新人 调查人员,并使用跨专业和跨学科的指导方法对他们进行培训;以及3) 评估范例培训计划,以实现学习目标、成功和长期 实习生的生产力和职业发展。该培训计划面向医学博士、药学博士和其他临床医生 博士级别的专家是基于四个前提的:1)基因组医学必须由一个干部来推动 来自不同专业领域的临床医生和博士科学家;2)团队方法是必不可少的;3)基因组 医学将需要一支多元化的领导队伍;4)佛罗里达大学是这方面的理想环境 训练。为了培训个人以满足这些需求,范式将提供一个多年的、综合的、 多学科计划由四个主要组成部分组成:1)必修课和 选修课程;2)指导研究部分,涉及在 指导一位有成就的基因组医学科学家和临床医生;3)临床基因组医学 将受训人员纳入基因组医学临床实践环境的组成部分;以及4)专业人员 发展部分,包括研究诚信培训;行政、财政和监管培训; 以及拨款的写作技巧。这四个组成部分的培训将根据以下方面的经验和需求量身定做 每个受训人员,但将集中在UF的三个专业核心:药物基因组学,癌症基因组学, 和疾病易感性遗传学/基因组学。该项目将由两位非常有成就的领导人领导, 该领域拥有一支才华横溢、协作能力强的多学科导师队伍。范型将 进行持续的评估和质量改进,以确保学员的长期成功。vt.在.的基础上 计划完成后,每个受训人员将被期望拥有使他们能够 应对基因组医学证据生成和临床应用方面的挑战。
英文摘要
ABSTRACT Healthcare professionals, genomic scientists, and numerous other stakeholders are embracing the advances in healthcare that are possible, and with increasing frequency are being delivered, through approaches that employ genomics to improve care and patient outcomes. To ensure that we can continue to expand upon and deliver the full potential of such an approach requires a highly qualified cadre of clinician-scientists, scientists, and clinicians working collaboratively to advance discoveries and implementation in genomic medicine. This proposal for continuation of our post-doctoral genomic medicine training program, “Program for Applied Research and Development in Genomic Medicine or PARADIGM,” leverages our successes and lessons learned from the first cycle of funding to: 1) refine an integrated training program in genomic medicine, which includes didactic, research, clinical, and professional development activities; 2) recruit promising junior investigators and train them using an interprofessional and interdisciplinary mentoring approach; and 3) evaluate the PARADIGM training program for achievement of learning objectives, success, and long-term productivity and career progress of trainees. This training program for MDs, PharmDs, PhDs, and other clinical specialists at the doctoral level is based on four premises: 1) Genomic medicine must be advanced by a cadre of clinicians and PhD scientists from a variety of specialty areas; 2) a team approach is essential; 3) genomic medicine will require a diverse workforce of leaders; 4) the University of Florida is an ideal environment for this training. To train individuals to meet these needs, PARADIGM will provide a multi-year, integrated, multidisciplinary program comprised of four major components: 1) a Didactic component of required and optional coursework; 2) a Mentored Research component involving a defined research project under the mentorship of an accomplished genomic medicine scientist and clinician; 3) a Clinical Genomic Medicine component that integrates trainees into the genomic medicine clinical practice setting; and 4) a Professional Development component including training in research integrity; administrative, fiscal and regulatory training; and grant-writing skills. Training across these four components will be tailored to the experience and needs of each trainee, but will be concentrated in three cores of expertise at UF: pharmacogenomics, cancer genomics, and disease susceptibility genetics/genomics. The program will be led by two highly accomplished leaders in the field together with a cadre of highly talented, collaborative, multidisciplinary mentors. PARADIGM will undergo continuous evaluation and quality improvement to ensure long-term success of the trainees. Upon program completion, each trainee will be expected to possess knowledge and skills that will enable them to manage the challenges of evidence generation and clinical use of genomic medicine.
期刊论文(23)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1245/s10434-021-10551-8
发表时间: 2021-10
期刊: Annals of surgical oncology
影响因子: 3.7
作者: [Herremans KM, Cribbin MP, Riner AN, Neal DW, Hollen TL, Clevenger P, Munoz D, Blewett S, Giap F, Okunieff PG, Mendenhall NP, Bradley JA, Mendenhall WM, Mailhot-Vega RB, Brooks E, Daily KC, Heldermon CD, Marshall JK, Hanna MW, Leyngold MM, Virk SS, Shaw CM, Spiguel LR]
通讯作者: Spiguel LR
It begins with the search committee: Promoting faculty diversity at the source.
首先是遴选委员会:从源头上促进教师多样性。
DOI: 10.1016/j.amjsurg.2021.08.027
发表时间: 2022
期刊: American journal of surgery
影响因子: 3
作者: [Arjani,Simran, Tasnim,Sadia, Sumra,Hibba, Zope,Madhushree, Riner,AndreaN, Reyna,Chantal, Henry,Marion, Anand,Tanya]
通讯作者: Anand,Tanya
ASO Visual Abstract: A 5-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1-4N1-3M0 Breast Cancer.
ASO 视觉摘要:乳腺外科医生在 ALND 治疗临床 T1-4N1-3M0 乳腺癌时的 5 年淋巴经验。
DOI: --
发表时间: 2021
期刊: Annals of surgical oncology
影响因子: 3.7
作者: [Herremans,KellyM, Cribbin,MorganP, Riner,AndreaN, Neal,DanW, Hollen,TracyL, Clevenger,Pamela, Munoz,Derly, Blewett,Shannon, Giap,Fantine, Okunieff,PaulG, Mendenhall,NancyP, Bradley,JulieA, Mendenhall,WilliamM, Vega,RaymondBMailhot]
通讯作者: Vega,RaymondBMailhot
DOI: 10.1007/s00423-023-03047-4
发表时间: 2023-08-15
期刊: LANGENBECKS ARCHIVES OF SURGERY
影响因子: 2.3
作者: [Uijterwijk, Bas A., Kasai, Meidai, Lemmers, Daniel H. L., Chinnusamy, Palanivelu, van Hilst, Jony, Ielpo, Benedetto, Wei, Kongyuan, Song, Ki Byung, Kim, Song C., Klompmaker, Sjors, Jang, Jin-Young, Herremans, Kelly M., Bencini, Lapo, Coratti, Andrea, Mazzola, Michele, Menon, Krishna, V, Goh, Brian K. P., Qin, Renyi, Besselink, Marc G., Abu Hilal, Mohammed]
通讯作者: Abu Hilal, Mohammed
共 17 条
    Preemptive pharmacogenetic testing in medically underserved populations
    • 批准号:
      10228297
    • 项目类别:
    • 资助金额:
      $75.0万
    • 财政年份:
      2021
    • 负责人:
      Julio David Duarte
    • 依托单位:
    Preemptive pharmacogenetic testing in medically underserved populations
    • 批准号:
      10673936
    • 项目类别:
    • 资助金额:
      $83.29万
    • 财政年份:
      2021
    • 负责人:
      Julio David Duarte
    • 依托单位:
    Improving treatment personalization for pulmonary hypertension associated with diastolic heart failure
    • 批准号:
      9039103
    • 项目类别:
    • 资助金额:
      $17.69万
    • 财政年份:
      2015
    • 负责人:
      Julio David Duarte
    • 依托单位:
    海外基金